Moderna, Inc. (MRNA) shares fell 11.5% in early trading Wednesday after the company announced that the FDA had issued a refusal-to-file letter for its mRNA flu vaccine application, citing concerns related to the trial design. The company is seeking an urgent meeting with the agency and has already submitted applications in Europe, Canada, and Australia.